WebMay 11, 2024 · The FIGHT-202 study evaluated the efficacy and safety of pemigatinib in patients with advanced, unresectable, or metastatic CCA who had progressed on one or more prior lines of systemic therapy. 15 As part of FIGHT-202, ... (FIGHT-302; ClinicalTrials.gov identifier: NCT03656536). 30. WebFeb 2, 2024 · Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were …
302nd Fighter Squadron - Wikipedia
WebTPS592 Background: For advanced CCA, standard of care 1L systemic treatment is GEM + CIS. Genetic alterations in intrahepatic CCA provide potential therapeutic targets. … WebJul 17, 2024 · We describe the study design of FIGHT-302, an open-label, randomized, active-controlled, multicenter, global, Phase III study comparing the efficacy and safety … 3 慶弔休暇
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for ...
WebJul 17, 2024 · FIGHT-302. FIGHT-302 is a global, Phase III, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin … WebFeb 22, 2024 · In addition, a randomised phase III study (FIGHT-302) is underway to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin as first … WebMay 6, 2024 · Pemigatinib is currently being studied in FIGHT-302 ... Phase 3 study of BGJ398 (oral infigratinib) in first line chol-angiocarcinoma with FGFR2 gene fusions/translocations. Updated January 27, 2024. 3或2